Compare Biogen Inc (BIIB) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Gemini Space Station Inc — how do they compare? Biogen Inc trades at $205.41 (market cap $30.13B), while Gemini Space Station Inc trades at $4.02 (market cap $512.05M). The key difference: Biogen Inc is far larger — about 58.8× Gemini Space Station Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | GEMI | |
|---|---|---|
Market Cap | $30.13B | $512.05M |
Sector | Health | Technology |
52-Week High | $216.63 | $32.52 |
52-Week Low | $128.93 | $3.90 |
Enterprise Value | $37.20B | $502.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
GEMI trades at $4.04, down 1.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $582.81M in 2025 on revenue of $179.57M, with negative gross and net income margins. Recent news includes a $100M investment from Winklevoss Capital and multiple class-action lawsuits alleging securities law violations.
The outlook remains challenging due to persistent losses and legal overhangs, though analyst consensus suggests a potential upside to $6.33. Key risks include ongoing unprofitability, competitive pressures in financial services, and regulatory scrutiny. Investment opportunity hinges on the company's ability to achieve profitability and navigate legal challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
